LVGO - Livongo Health, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
+0.80 (+3.47%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close23.06
Bid22.32 x 900
Ask23.99 x 800
Day's Range22.69 - 23.92
52 Week Range21.90 - 45.68
Avg. Volume1,411,895
Market Cap2.253B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.95
Earnings DateSep 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est43.56
Trade prices are not sourced from all markets
  • Livongo Execs on IPO, Staff Members with Chronic Conditions
    Meredith Videos

    Livongo Execs on IPO, Staff Members with Chronic Conditions

    Fortune's Sy Mukherjee interviews Livongo CEO Zane Burke and President Jennifer Schneider at NASDAQ Marketsite in Manhattan, NY.

  • Why Meredith, Livongo Health, and First Majestic Silver Slumped Today
    Motley Fool

    Why Meredith, Livongo Health, and First Majestic Silver Slumped Today

    Even high hopes on trade weren't enough to lift these stocks.

  • Why Livongo Health Stock Is Tanking Today
    Motley Fool

    Why Livongo Health Stock Is Tanking Today

    Shares sink after the newly public company reports mixed quarterly results.

  • MarketWatch

    Livongo's stock gains after wider-than-expected loss, but revenue rose above forecasts

    Shares of Livongo Health Inc. rose 1% in premarket trading Thursday, after the digital health company reported its first quarterly results since going public, with a wider-than-expected loss but revenue that rose above forecasts. The net loss widened to $14.3 million, or 76 cents a share, from $6.2 million, or 38 cents a share, in the year-ago period. Excluding non-recurring items, the adjusted loss per share was 46 cents, compared with the FactSet per-share loss consensus of 15 cents. Revenue rose 156% to $40.9 million, above the FactSet consensus of $39.7 million. Enrollment for Diabetes Members grew 140% to 192,934, while clients increased 92% to 720. For the third quarter, Livongo expects revenue of $42 million to $43 million, surrounding the FactSet consensus of $42.3 million. The stock has lost 19% since it closed at $38.10 on its first day of trading on July 25, while the S&P 500 has declined 2.2% over the same time.


    Livongo Rises on Narrower-Than-Expected Loss, Revenue Jump of 156%

    Shares of healthcare industry solutions provider Livongo Health were rising in premarket trading Thursday after the company reported a second-quarter loss narrower than analysts' expectations. The Mountain View, California-based company reported a 156% increase in year-over-year revenue to $40.

  • Benzinga

    Morgan Stanley: Buy The Dip In Livongo Health

    Shares of Livongo Health Inc (NASDAQ: LVGO ) have lost nearly 20% since its late July IPO , and investors should take advantage of the discount valuation, according to Morgan Stanley. The Analyst Ricky ...

  • GlobeNewswire

    Livongo to Present at Morgan Stanley 17th Annual Healthcare Conference

    MOUNTAIN VIEW, Calif., Aug. 27, 2019 -- Livongo Health, Inc. (Nasdaq: LVGO), a leading Applied Health Signals company empowering people with chronic conditions to live better.

  • GlobeNewswire

    Livongo Founder and Executive Chairman Glen Tullman Honored with Robert F. Kennedy Human Rights Ripple of Hope Award

    Today, Livongo announced that Founder and Executive Chairman Glen Tullman will be honored with a Robert F. Kennedy Human Rights Ripple of Hope Award for his career focused on improving the safety, empathy, and efficiency of our healthcare system. The Ripple of Hope Award celebrates leaders of the international business, entertainment, and activist communities who have demonstrated a commitment to social change. Past honorees include President Barack Obama, Archbishop Desmond Tutu, Bono, George Clooney, and Robert F. Smith.

  • Benzinga

    Sell-Side Mixed On Surging Livongo Health

    Livongo Health Inc (NASDAQ: LVGO) shares have bumped up more than 30% since the company went public at the end of July, raising interest in the digital health platform company. KeyBanc Capital Market's Donald Hooker initiated coverage of Livongo Health with an Overweight rating and $46 price target. Livongo uses technology to manage chronic disease treatment, mostly in patients with diabetes, and both analysts said the company’s business model appear to give it a long growth runway.

  • 2 New Digital Health Stocks for Your Watch List
    Motley Fool

    2 New Digital Health Stocks for Your Watch List

    Here's why you'll want to keep both eyes on these market leaders.

  • GlobeNewswire

    Livongo to Release Results for the Second Quarter of Fiscal Year 2019

    MOUNTAIN VIEW, Calif., Aug. 07, 2019 -- Livongo Health, Inc. (Nasdaq: LVGO) today announced it will hold a conference call on Thursday, September 5, 2019 at 8:00 a.m. Eastern.

  • GlobeNewswire

    Livongo Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

    MOUNTAIN VIEW, Calif., July 29, 2019 -- Livongo Health, Inc., (Nasdaq: LVGO) today announced the closing of its initial public offering of 14,590,050 shares of its common stock.

  • GlobeNewswire

    Livongo Announces Pricing of Initial Public Offering

    MOUNTAIN VIEW, Calif., July 24, 2019 -- Livongo Health, Inc. (Livongo) today announced the pricing of its initial public offering of 12,687,000 shares of its common stock at a.

  • Benzinga

    Livongo Health IPO: What You Need To Know

    The company's shares have been approved for listing on the Nasdaq under the ticker symbol LVGO. Kinnevik Online AB, which holds more than 5% of Livongo's outstanding capital stock, has expressed willingness to buy up to $20 million worth of shares or about 800,000 shares, the company said in the filing. Morgan Stanley, Goldman Sachs and JPMorgan are the lead underwriters for the offering.

  • Benzinga

    IPO Outlook For The Week: Biotech, Health Analytics, Sports And Solar Power

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Castle Biosciences Inc (NASDAQ: CSTL ) will issue more than 3.33 million ...